Abstract: A flame simulator of an electric fireplace, including: a light source (1); a flame board (3); a flame projection screen (4); and a rotary drum (2); wherein the light source (1) is provided in the rotary drum (2); the rotary drum (2) is transparent and a light-concentrating block (20) is provided on a surface thereof; a flame pattern (31) is provided on the flame board (3); light concentrated by the light-concentrating block (20) is projected onto the flame board (3) and reflected by the flame board (3) to the flame projection screen (4) for forming a flame image. The flame is bright and has a sufficient dynamic effect. The rotary drum (2) and the light-concentrating block (20) can be made by injection molding for a simple structure and convenient production.

Abstract: A flame simulator of an electric fireplace, including: a light source (1); a flame board (3); a flame projection screen (4); and a rotary drum (2); wherein the light source (1) is provided in the rotary drum (2); the rotary drum (2) is transparent and a light-concentrating block (20) is provided on a surface thereof; a flame pattern (31) is provided on the flame board (3); light concentrated by the light-concentrating block (20) is projected onto the flame board (3) and reflected by the flame board (3) to the flame projection screen (4) for forming a flame image. The flame is bright and has a sufficient dynamic effect. The rotary drum (2) and the light-concentrating block (20) can be made by injection molding for a simple structure and convenient production.

Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O?; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Abstract: The present invention is directed to the method of increasing the metabolic stability of adamantane containing compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 (11-beta-HSD-1) enzyme. The stability is achieved by substitutions of the adamantane ring.

Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O?; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.